Loading organizations...
RazorMetrics delivers a cloud-based platform offering pharmacy technology solutions to reduce drug costs. Its proprietary system automatically identifies and executes cost-saving opportunities via medication switching, deprescription, and deduplication. Integrating into prescriber workflows, the platform empowers providers to optimize decisions, lowering medication expenses for members and sponsors, enhancing pharmacy benefit value.
Founded in 2018, RazorMetrics was established by interventional cardiologist Dr. Siva Mohan and serial entrepreneur Tom Dorsett. Dr. Mohan's clinical experience revealed how opaque medication pricing created substantial patient barriers. This insight, combined with Dorsett’s background, drove scalable solutions addressing pharmaceutical affordability.
RazorMetrics serves health plan members and sponsors, including self-funded employers, by improving drug affordability and access. The company’s vision is to tackle America's drug affordability crisis with scalable, physician-friendly tools. These solutions reduce costs and foster adherence, ensuring patients consistently access essential medications.
RazorMetrics has raised $6.0M across 1 funding round.
RazorMetrics has raised $6.0M in total across 1 funding round.
RazorMetrics has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $6M Series A | Sopris Capital | Bain Capital Crypto, OAK HC/FT, Joel Trammel, Jonathan Weiner | Announced |
# RazorMetrics: High-Level Overview
RazorMetrics is a healthcare technology company that uses AI-powered solutions to reduce prescription drug costs for health plans, self-insured employers, and healthcare organizations.[1][2] Founded in 2018 by an interventional cardiologist and serial technology entrepreneur, the company has built a SaaS platform that automates cost-saving opportunities through medication switching, deprescription, and deduplication—all while keeping clinical decisions in physicians' hands.[1][4] The company operates from Austin, Texas, and serves a diverse client base including PBMs, health plans, brokers, and self-funded employers across the United States.[1][2]
RazorMetrics addresses a critical pain point in American healthcare: the rising cost of prescription medications. Rather than requiring healthcare providers to navigate complex external systems or members to opt into additional programs, the platform integrates seamlessly into existing prescriber workflows, making cost containment invisible to end users while delivering measurable savings.[2][3] The company has demonstrated exceptional growth momentum, expanding 11x from 2022 to 2023, and has already helped clients reduce drug spend by $300 million annually.[2][3]
RazorMetrics emerged from a clear mission: to remove the health barrier created by high drug costs.[4] The company was founded in 2018 by a team combining clinical expertise—an interventional cardiologist—with technology entrepreneurship, recognizing that modern AI and automation could streamline the notoriously complex world of prescription cost management.[4] This physician-led founding principle remains central to the company's identity, ensuring that technology serves clinical decision-making rather than replacing it.
The company's early trajectory reflects strong market demand. By 2021-2022, RazorMetrics achieved 2x growth; the following year saw explosive 11x expansion, signaling that healthcare organizations were actively seeking solutions to control pharmacy spend as budgets tightened.[2] This rapid scaling required the company to build out its executive team and support infrastructure—a challenge CEO Tom Dorsett highlighted as successfully navigated in early 2024.[2]
RazorMetrics distinguishes itself through several key advantages:
RazorMetrics operates at the intersection of two powerful healthcare trends: the urgent need to control pharmaceutical costs and the maturation of AI-driven automation in clinical workflows. As employers and health plans face mounting pressure to manage drug spend without compromising care quality, RazorMetrics represents a new category of "invisible" healthcare technology—solutions that deliver measurable financial impact while remaining transparent to end users.
The company's success reflects broader market forces: self-funded employers increasingly demand direct control over healthcare costs, PBMs face pressure to demonstrate value beyond traditional rebate models, and health plans seek differentiation through member-friendly cost management. RazorMetrics' physician-led approach addresses a critical gap—most cost-containment solutions either burden prescribers with additional workflow friction or alienate members with complex opt-in requirements. By eliminating both friction points, the company influences how the healthcare technology ecosystem thinks about cost control as a clinical, not just administrative, function.
The company's ranking as No. 12 on Deloitte's 2025 Technology Fast 500 underscores its influence within the broader healthtech innovation landscape.[6]
RazorMetrics is positioned to become a foundational layer in pharmacy benefit management. As drug costs continue rising and healthcare organizations exhaust traditional cost-containment strategies, demand for AI-driven, workflow-integrated solutions will only intensify. The company's 11x growth trajectory, expanding partnerships with major PBMs and health plans, and strong unit economics (guaranteed ROI doubling) suggest it has achieved product-market fit at scale.
The next phase will likely involve deepening integrations with major healthcare platforms, expanding internationally, and potentially exploring adjacent cost-containment opportunities beyond pharmacy. The company's commitment to accessibility and physician-centric design positions it well to maintain trust as it scales—a critical advantage in healthcare, where adoption depends on clinician buy-in.
What makes RazorMetrics compelling is not just its growth rate, but its fundamental insight: the most effective healthcare cost control happens when technology serves clinicians, not the reverse. In an industry often criticized for prioritizing administrative efficiency over patient care, RazorMetrics offers a different model—one where savings and clinical integrity reinforce rather than compete with each other.
RazorMetrics has raised $6.0M in total across 1 funding round.
RazorMetrics's investors include Sopris Capital, Bain Capital Crypto, Oak HC/FT, Joel Trammel, Jonathan Weiner.
